Padcev + Keytruda reach primary endpoint for some bladder cancers, phase III trial shows

Population-based cancer surveillance is a national treasure at risk

There is a silent crisis in cancer research that underpins nearly all aspects of the work we do to combat this disease.

September 26, 2025

By Eric B. Durbin, Karen L. Knight, Betsy Kohler and Sarah Nash

Earlier diagnosis, better outcomes: Telemedicine has found a home in oncology

We are rapidly approaching the Sept. 30 planned expiration of telemedicine coverage under Medicaid. Letting this authorization expire is short-sighted. As an oncologist, I believe there are multiple compelling, non-pandemic reasons for telemedicine to remain a permanent fixture in cancer care.

Break Through Cancer launches a $15M multi-institute pediatric osteosarcoma research initiative

Break Through Cancer has launched the Defying Osteosarcoma TeamLab, an initiative that brings together more than 20 researchers from eight institutions in a coordinated, multi-year effort focused on improving pediatric osteosarcoma care.

September 26, 2025

Vol.51 No.35

Clinical Roundup

Tecvayli + Darzalex Faspro achieves 100% MRD negativity in newly diagnosed MM, phase II study shows

An investigational immune-based induction regimen with Tecvayli (teclistamab-cqyv) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) demonstrated meaningful clinical efficacy in transplant-eligible patients with newly diagnosed multiple myeloma.

September 26, 2025

Vol.51 No.35

Letter To The Editor

Urgently needed: A funding mechanism to insulate cancer research from political whims

Jonathan Mahler’s article in the Sept. 14 issue of The New York Times Magazine provided an excellent overview of the Trump administration’s assault on cancer research.

AACR survey finds overwhelming public support for federal funding for medical and cancer research

The American Association for Cancer Research released the results of a national survey measuring voters’ attitudes about federal funding for medical research, which found very high levels of support for federal funding for medical and cancer research across the electorate.

September 19, 2025

Vol.51 No.34

By Claire Marie Porter

Padcev + Keytruda reach primary endpoint for some bladder cancers, phase III trial shows

YOU MAY BE INTERESTED IN

Population-based cancer surveillance is a national treasure at risk

Earlier diagnosis, better outcomes: Telemedicine has found a home in oncology

Break Through Cancer launches a $15M multi-institute pediatric osteosarcoma research initiative

Tecvayli + Darzalex Faspro achieves 100% MRD negativity in newly diagnosed MM, phase II study shows

Urgently needed: A funding mechanism to insulate cancer research from political whims

AACR survey finds overwhelming public support for federal funding for medical and cancer research

Renew today!

Subscriber content

Never miss an issue!

Login